Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TP53 was mutated in 13/63 (21%) cases, including 5/7 (71%) leukemic non-nodal and 8/56 (14%) conventional mantle cell lymphoma.
|
31296581 |
2020 |
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
|
30626249 |
2019 |
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Seemingly indolent L-MCL may harbor subclonal TP53 mutations which may serve as a useful biomarker for prognostication, therapeutic planning, follow-up monitoring, and early detection of clonal expansion.
|
31132650 |
2019 |
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results: i) confirm that TP53 disruption identifies a high-risk population characterized by poor sensitivity to conventional or intensified chemotherapy; ii) provide the pivotal evidence that patients harboring KMT2D mutations share the same poor outcome as patients harboring TP53 disruption; and iii) allow to develop a tool for the identification of high-risk mantle cell lymphoma patients for whom novel therapeutic strategies need to be investigated.
|
31537689 |
2019 |
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.
|
30537212 |
2019 |
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
When adjusted for MCL International Prognostic Index (MIPI) or combined MCL-International Prognostic Index (MIPI-c), TP53 and WHSC1 mutations were the most important prognostic factors in MCL (P < 0.05).
|
29755111 |
2018 |
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
|
30146365 |
2018 |
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Demonstration of TP53 and NSD2 mutations in patients who developed blastoid transformation and ATM and TP53 mutations in patients who progressed, opens the door for future investigations in ibrutinib-refractory MCL.
|
30175400 |
2018 |
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, TP53 immunohistochemistry is a suitable test for routine diagnostic practice to assess MCL prognosis.
|
29196411 |
2018 |
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Reported findings of indolent presentation of MCL include: lack of B symptoms, normal serum lactic dehydrogenase (LDH) and β2-microglobulin levels (β2M), low MCL-International Prognostic Index (MIPI) score, maximum tumor diameter less than 3 cm, spleen size < 20 cm, positron emission tomography/computerized tomography with the Standard Uptake Value max <6, Ki-67 less than 30%, with some particular immunophenotype, such as CD5 and CD38 negative, markedly increased CD23 positive lymphocytes proportions, high expression of CD200, kappa light chain restriction, without C-myc, TP53 and NOTCH1/2 mutations, non-blastoid/pleomorphic histology, and no tumor growth on reevaluation every 2~3 months (followed for at least 6 months).
|
29246179 |
2017 |
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with highly proliferative MCL and those with TP53 mutations tend to respond poorly despite intensive cytotoxic therapies.
|
28899853 |
2017 |
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted immunohistochemical staining of C-MYC, Programmed cell death ligand 1 (PD-L1), CD8, Ki-67, p53 and SRY (sex determining region Y) -11 (SOX11) to investigate their expression in 64 patients with MCL.
|
28626618 |
2017 |
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deletion and mutation, usually associated, of ATM or TP53 are frequent in Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma.
|
28284458 |
2017 |
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The presence of TP53 mutation was associated with shorter overall survival (OS) and progression-free survival (PFS) in MCL.
|
28791403 |
2017 |
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These studies demonstrate the potential for diclofenac as novel therapeutic agent in MCL independent of p53 status.
|
27074052 |
2016 |
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Backtracking analysis using quantitative PCR specifically detecting an MCL-restricted focal deletion of TP53 revealed that the pre-MCL clone appeared in the bone marrow and peripheral blood of the patient approximately 4 years before the clinical manifestation of MCL.
|
27407063 |
2016 |
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite immunochemotherapy, high-dose cytarabine, and ASCT, younger MCL patients with deletions of CDKN2A (p16) and TP53 show an unfavorable prognosis and are candidates for alternative therapeutic strategies.
|
26022239 |
2015 |
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MDM4, the newly discovered modulator of p53 protein, is frequently amplified in various solid tumors such as cutaneous melanoma, retinoblastoma and hematological malignances such as chronic lymphocytic leukemia, acute myeloid leukemia and mantle cell lymphoma.
|
26567881 |
2015 |
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and/or 13q14.
|
24852242 |
2014 |
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutation was insufficiently an independent prognostic factor in patients with MCL at advanced stage.
|
22057359 |
2012 |
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TP53 alterations are strongly associated with a high proliferation index and aggressive behavior in mantle cell lymphoma.
|
22315488 |
2012 |
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that PARPi may enhance the therapeutic efficacy of DNA damaging agents on MCL through TP53-independent mechanisms without requiring the inhibition of either ATM or BRCA2.
|
22170260 |
2012 |
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mantle cell lymphoma cell lines with known p53 status were treated with GUT-70, a tricyclic coumarin derived from Calophyllum brasiliense, and the biological and biochemical consequences of GUT-70 were studied.
|
21139584 |
2011 |
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed the p53 tumor suppressor in tumor tissue of 33 patients with MCL.
|
20126990 |
2010 |
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.
|
20850924 |
2010 |